TEL AVIV, Israel and BETHESDA, Maryland, Oct. 7, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid based cancer medicine, today announced that it has appointed the Company's Founder as a new Director and Member of its Board.
Itamar Borochov, 62, is an environmentalist with vast experience as an entrepreneur in the medical cannabis field, with broad experience in management and finance in medical cannabis companies which operate in regulated markets. Mr. Borochov was the original Founder of Cannabics Pharmaceuticals Inc.
Eyal Barad, CEO and Co-Founder, said, "The entire team is pleased to have Itamar return to the Board at a very significant time, and I am sure his intimate knowledge and industry experience will significantly contribute to the company as we move into our next planned phases."
Mr. Borochov said: "The company's shareholders requested that I become reengaged and join the Board, to which I immediately agreed. At this point the company's groundbreaking research is moving into a go-to market strategy phase, through various collaborations. My immediate goal is to assist and facilitate these collaborations, which will bring us closer to realizing our vision of personalizing regulated medical cannabinoid-based cancer treatments."
Mr. Borochov's appointment to the board of directors was reported in the company's latest 8-K, filed on October 3rd, 2019.
About Cannabics Pharmaceuticals
Cannabics Pharmaceuticals Inc. (OTCQB:CNBX) is a U.S public company that is developing a platform which leverages novel drug-screening tools and artificial intelligence to create cannabinoid-based therapies for cancer that are more precise to a patient's profile. By developing tools to assess effectiveness on a personalized basis, Cannabics is helping to move cannabinoids into the future of cancer therapy. The company's R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and Cancer. For more information, please visit www.cannabics.com.
For more information, please visit www.Cannabics.com.
For the latest updates on Cannabics Pharmaceuticals follow the company on Twitter@Cannabics, Facebook@CannabicsPharmaceuticals, LinkedIn, and on Instagram @Cannabics_Pharmaceuticals.
Certain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. Such statements include but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission including, without limitation, our latest 10-Q Report filed on July 15th, 2019. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Cannabics Pharmaceuticals Inc. which are condoned by the Company must emanate from the Company itself and bear our name as its source.
SOURCE Cannabics Pharmaceuticals Inc.